Teva leads march on Capitol Hill

Teva has spent $5.5 million on lobbying in the US Congress in seven years. "Globes" reveals which other Israeli companies have been spending money on lobbying and how much.

How can Israeli companies, which have not contributed to the election campaign of one party or another, and which do not have contacts among American politicians, extend their reach to the US, and influence decision making in the world's largest democracy? The answer should come as no surprise: they hire lobbyists to serve as their long arm, and promote their interests in the US Congress, the Senate, the White House, on special committees, and with any regulatory body where influence is required. One company that has spent a considerable sum on promoting its interests is pharmaceutical giant Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA; TASE: TEVA), the world's largest generic drugs company.

A report published by the United States Senate Office of Public Records, which details the annual expenditure on lobbying throughout the years (since the enactment of the Lobbying Disclosure Act of 1995) reveals that, during the first half of 2007, Teva paid Washington-based lobbying firm Timmons & Company $200,000. The report, which was published at the beginning of the month, said that Teva had engaged the company to promote, among other things, an amendment to the Public Health Service Act. The amendment is likely to pave the way for regulatory approval of biogeneric drugs - a field to which Teva has devoted considerable efforts. It is also seeking amendments to laws relating to the US Food and Drug Administration (FDA), as well changes to regulations governing health insurance cover for the use of generic drugs.

$200,000 is the amount spent since the beginning of the year, but the sum over recent years is a lot higher. An examination by "Globes" of Senate records reveals that, since 2002, the first recorded entry, Teva has spent a total of $5.5 million. This is a small sum for a company with more than $3 billion in cash, but a sizeable amount to invest in lobbying, and Teva is probably the Israeli company that spends the most on this kind of activity. Teva declined to confirm the figure.

Teva generally promotes generics and legislation that governs it. On the other side of the fence are the big pharmaceutical companies that sell mainly ethical drugs, and they invest more. A lot more. Pfizer Inc. (NYSE: PFE), for example, spent almost $12 million on lobbying in 2006 - including on issues not related to the blocking of generics - while Merck & Co. Inc. (NYSE: MRK) invested a few million dollars last year - $4 million to be precise.

Teva - supporting the professionalizing of the US judiciary

Teva has worked, and is still working with a number of lobbying firms, including Wilkie Farr & Gallagher LLP, The Washington Group, MFJ International LLC, which is also working together with the Generic Pharmaceutical Association, Kirkland & Ellis LLP, Artemis Strategies, and others. Every year, the issues on the agenda are slightly different. One of the ideas that Teva wished to promote in 2006 was a pilot scheme introduced in certain district courts in the US, aimed at promoting judicial expertise on patents. It also sought to promote patent reforms that year.

Interestingly, the person whose signature appears on some of the documents filed by Teva with the Senate is Debra Barrett, Teva USA's VP of government affairs. Amazingly, her surname is similar to that of George Barrett, president and CEO of Teva North America, and Teva Group VP, and her first name is the same as Barrett's wife. Teva said that Barrett's wife was indeed called Debra, but that it was not the same person.

Moreover, some of the earlier documents that Teva filed up to 2005 bore the signature of someone called Judith Marth, who also served as Teva USA VP of government affairs. In this case the similarity in name to current Teva USA president and CEO William S. Marth is no coincidence. Judith Marth (nee Milford) is indeed William Marth's wife. The two met at Teva, but Judith has since left.

In any event, Teva may have a high profile, and a reputation for investing effort in changing public opinion on Capitol Hill, but it is no by no means the only one to do so, although as mentioned earlier, the sums it spends on this are a lot higher than those spent by other companies. Check Point Software Technologies Ltd. (Nasdaq: CHKP), for example, paid the Normandy Group $20,000 to "raise general issues relating to business restrictions, and other commercial issues in the White House and Senate." One can only assume that this actually referred to Check Point's attempts to acquire Sourcefire, an acquisition that fell through after it was blocked by the US administration.

Other examples of lobbying expenditure (some of which were calculated by the website Open Secrets, a site run by the Washington-based Center for Responsive Politics) are: Tefen Yazamot Ltd., controlled by Stef Wertheimer, which paid a total of $550,000 to lobbying firms Livingston Group LLC and Piper Rudnick LLP (which later became DLA Piper) to promote key economic issues; Merhav Group, which has spent $980,000 since 1998 (with an interval between 2000-2002); and Zoran Corp. (Nasdaq: ZRAN), which spent $280,000 on lobbying the Senate on digital television in 2005-2006. In addition, the Technion Israel Institute of Technology spends around $40,000 a year on lobbying, while Nilit Ltd has spent tens of thousands of dollars a year in lobbying since 1999, reaching $120,000.

The defense industries are fairly active too, and most of them are clients of Zvi Rafiah. Israel Aerospace Industries Ltd. (IAI) has spent tens of thousands of dollars a year since 1998 (reaching a record $310,000 in 2006). ImageSat International NV, which planned to float on Nasdaq, spent $120,000 in 2004-2005 on marketing satellite services to US government companies. Tadiran Electronic Systems Ltd. spent $60,000 in 2006 on the securing of finance for its products. Elbit Systems Ltd. (Nasdaq: ESLT; TASE: ESLT) subsidiary Elisra Group is another lobbying client from the defense industry, while Rafael Armament Development Authority Ltd. spent almost $150,000 a year until 2002, and $520,000 in 2005-2006.

Israeli banks, such as Bank Hapoalim (LSE: BKHD; TASE: POLI), Israel Discount Bank (TASE: DSCT), Israel Discount Bank of New York, Union Bank of Israel (TASE: UNON), and Bank Leumi (TASE: LUMI), have also set aside funds for lobbying in the US on, among other things, taxation and regulation. Private Israeli citizens also number among the clients of lobbyists on Capitol Hill. In 2000, for example, businessman Baruch Ivcher spent $20,000 on the promotion of press freedom in Peru. Ivcher, a multimillionaire whose business interests in Israel include the ownership of a number of media organizations, is currently one of the franchisees of the Coffee Bean & Tea Leaf in Israel.

Published by Globes [online], Israel business news - www.globes.co.il - on August 9, 2007

© Copyright of Globes Publisher Itonut (1983) Ltd. 2007

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018